Gamal Esmat

Gamal Esmat

Auto-generated profile, based on publicly available information

Gamal Esmat

Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2011 in Liver International
Verified
Journal Article
Open access
PDF file
WSWilliam Sievert
William Sievert
IAIbrahim Altraif
Ibrahim Altraif
HRHomie Razavi
Homie Razavi
AAAyman Abdo
Ayman Abdo
EAEzzat Ali Ahmed
Ezzat Ali Ahmed
FNFrancesco Negro
Francesco Negro
Background: The hepatitis C pandemic has been systematically studied and characterized in North America and Europe, but this important public health problem has not received equivalent attention in other regions.Aim: The objective of this systematic review was to characterize hepatitis C virus (HCV) epidemiology in selected countries of Asia, Australia and Egypt, i.e. in a geographical area inhabited by over 40% of the global population.Methodology: Data references were identified through indexed journals and non‐indexed sources. In this work, 7770 articles were reviewed and 690 were selected based on their relevance.Results: We estimated that 49.3–64.0 million adults in Asia, Australia and Egypt are anti‐HCV positive. China alone has more HCV infections than all of Europe or the Americas. While most countries had prevalence rates from 1 to 2% we documented several with relatively high prevalence rates, including Egypt (15%), Pakistan (4.7%) and Taiwan (4.4%). Nosocomial infection, blood transfusion (before screening) and injection drug use were identified as common risk factors in the region. Genotype 1 was common in Australia, China, Taiwan and other countries in North Asia, while genotype 6 was found in Vietnam and other Southeast Asian countries. In India and Pakistan genotype 3 was predominant, while genotype 4 was found in Middle Eastern countries such as Egypt, Saudi Arabia and Syria.Conclusion: We recommend implementation of surveillance systems to guide effective public health policy that may lead to the eventual curtailment of the spread of this pandemic infection.

1 September 2013 in Journal of Advanced Research
Verified
Journal Article
Open access
TETamer Elbaz
Tamer Elbaz
GEGamal Esmat
Gamal Esmat
Schistosomiasis is an endemic disease in Egypt caused by the trematode Schistosoma which has different species. Hepatic schistosomiasis represents the best known form of chronic disease with a wide range of clinical manifestations. The pathogenesis of schistosomiasis is related to the host cellular immune response. This leads to granuloma formation and neo angiogenesis with subsequent periportal fibrosis manifested as portal hypertension, splenomegaly and esophageal varices. Intestinal schistosomiasis is another well identified form of chronic schistosomal affection. Egg deposition and granuloma formation eventually leads to acute then chronic schistosomal colitis and is commonly associated with polyp formation. It frequently presents as abdominal pain, diarrhea, tenesmus and anal pain. Definite diagnosis of schistosomiasis disease depends on microscopy and egg identification. Marked progress regarding serologic diagnosis occurred with development of recent PCR techniques that can confirm schistosomal affection at any stage. Many antischistosomal drugs have been described for treatment, praziquantel being the most safe and efficient drug. Still ongoing studies try to develop effective vaccines with identification of many target antigens. Preventive programs are highly needed to control the disease morbidity and to break the cycle of transmission.

9 August 2011 in Journal of Viral Hepatitis
Verified
Journal Article
Open access
PDF file
AHAngelos Hatzakis
Angelos Hatzakis
SWS. Wait
S. Wait
JBJ. Bruix
J. Bruix
MBM. Buti
M. Buti
MCM. Carballo
M. Carballo
HJH. L. A. Janssen
H. L. A. Janssen
Summary. Worldwide, the hepatitis B virus (HBV) and the hepatitis C virus (HCV) cause, respectively, 600 000 and 350 000 deaths each year. Viral hepatitis is the leading cause of cirrhosis and liver cancer, which in turn ranks as the third cause of cancer death worldwide. Within the WHO European region, approximately 14 million people are chronically infected with HBV, and nine million people are chronically infected with HCV. Lack of reliable epidemiological data on HBV and HCV is one of the biggest hurdles to advancing policy. Risk groups such as migrants and injecting drug users (IDU) tend to be under‐represented in existing prevalence studies; thus, targeted surveillance is urgently needed to correctly estimate the burden of HBV and HCV. The most effective means of prevention against HBV is vaccination, and most European Union (EU) countries have universal vaccination programmes. For both HBV and HCV, screening of individuals who present a high risk of contracting the virus is critical given the asymptomatic, and thereby silent, nature of disease. Screening of migrants and IDUs has been shown to be effective and potentially cost‐effective. There have been significant advances in the treatment of HCV and HBV in recent years, but health care professionals remain poorly aware of treatment options. Greater professional training is needed on the management of hepatitis including the treatment of liver cancer to encourage adherence to guidelines and offer patients the best possible outcomes. Viral hepatitis knows no borders. EU Member States, guided by the EU, need to work in a concerted manner to implement lasting, effective policies and programmes and make tackling viral hepatitis a public health priority.

28 June 2010 in Gut
Verified
Journal Article
Open access
PDF file
AMAya Mostafa
Aya Mostafa
MMMostafa K Mohamed
Mostafa K Mohamed
MSMohamed Saeed
Mohamed Saeed
AHAbubakr Hasan
Abubakr Hasan
AFArnaud Fontanet
Arnaud Fontanet
NCNish Chaturvedi
Nish Chaturvedi
Background Chronic hepatitis C (HCV) infection is associated with diabetes and favourable lipids. Objective To study the effect of this paradox on atherosclerosis and cardiometabolic response to HCV clearance. Design Cross-sectional study. Setting Egypt. Participants 329 chronically infected, 173 with cleared infection and 795 never infected participants aged ≥35 attended for baseline investigations. A subsample of 192, 115 and 187, respectively, underwent ultrasound. Main outcome measures Diabetes, fasting glucose, lipids and fat deposition on ultrasound. Carotid intima-media thickness (IMT) measured atherosclerosis. Results Diabetes prevalence was raised (10.1% (95% CI 6.6 to 13.6), p=0.04) in HCV chronic, and cleared (10.1% (5.6 to 14.8), p=0.08) individuals versus 6.6% (4.9 to 8.3) in those never infected. Mesenteric fat was raised in chronic (36.4 mm (34.5 to 38.2), p=0.004), and cleared infection (37.8 (35.6 to 40.0), p<0.0001) vs never infected (32.7 (31.0 to 34.4)). LDL cholesterol was lower in chronic (2.69 mmol/l (2.53 to 2.86), p<0.001), but similar in cleared (3.56 (3.34 to 3.78), p=0.4) versus never infected (3.45 (3.30 to 3.60)). Carotid IMT did not differ by infection status: 0.73 (0.70 to 0.76, p=0.4), 0.71 (0.66 to 0.75, p=0.9), 0.71 (0.68 to 0.74), respectively. Adjustment for cardiovascular risk factors increased IMT in chronic infection (0.76 (0.72 to 0.79), p=0.02) versus never infected individuals (0.70 (0.67 to 0.73)). Conclusions Hepatic function normalisation with HCV clearance may account for reversal of favourable lipids observed with HCV infection. Hyperglycaemia and visceral adiposity appear less amenable to HCV resolution. These different cardiovascular risk patterns may determine equivalent atherosclerosis risk by infection status. However, once these factors were accounted for, those with chronic infection had raised IMT, suggesting a direct effect of infection.

1 May 2009 in Phytomedicine
Verified
Journal Article
Closed access
SESamer S. El-Kamary
Samer S. El-Kamary
MSMichelle D. Shardell
Michelle D. Shardell
MAMohamed Abdel-Hamid
Mohamed Abdel-Hamid
SISoheir Ismail
Soheir Ismail
MEMohamed El-Ateek
Mohamed El-Ateek
GSG. Thomas Strickland
G. Thomas Strickland

7 June 2011 in Liver International
Verified
Journal Article
Closed access
PDF file
SWSteven T. Wiersma
Steven T. Wiersma
BMBrian McMahon
Brian McMahon
JPJean-Michel Pawlotsky
Jean-Michel Pawlotsky
CTChloe L. Thio
Chloe L. Thio
MTMark Thursz
Mark Thursz
GDGeoff Dusheiko
Geoff Dusheiko